RxDoctor Payments Data

Jorge Castriz, MD

Cardiovascular Disease · Great Falls, MTNPI 1811951601

Payments from drug & device makers

What this record shows

The money is spread across several categories — travel and lodging (52.0%), food and beverage and education — rather than concentrated in one kind of arrangement. 20 manufacturers reported payments, led by Abbott at 40.6% of the total. 2025 is the largest year on record at $2,458, 9.9 times the $248 reported in 2019.

$6,240in general payments, 2019–2025

Across 125 payments — averaging $49.92 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.

  • Abbott$3K
  • Medtronic$2K
  • Novartis$306
  • E.r. Squibb & Sons, L.L.C.$268
  • Abiomed$150
  • Impulse Dynamics (USA) Inc.$98
  • plus $486 from 14 others
$67,009in research payments, 2019–2025

Across 7 payments — averaging $9572.71 each. Payments tied to a research study. These frequently flow through the physician to a hospital or research institution rather than to the physician personally.

  • AstraZeneca$67K

What the payments were for

  • Travel & lodging$3,24252%
  • Food & beverage$2,98448%
  • Education$140%

General payments by program year

19
20
21
22
23
24
25

Who reported the general payments

Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.

What the payments were tied to

Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.

How this compares

$6,240 in reported general payments places this provider in the 75th percentile of 49 cardiovascular disease providers in Montana.

See all cardiovascular disease providers in Montana

Medicare billing

Part B allowed, 2024
$232,404
Medicare patients
856
Services billed
2,733

What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.

Most prescribed under Part D

DrugClaimsCost to plans & patients
EliquisApixaban437$377,154
XareltoRivaroxaban125$150,603
EntrestoSacubitril/Valsartan50$72,954
Repatha SureclickEvolocumab17$22,268
Metoprolol Succinate488$7,303
Dabigatran EtexilateDabigatran Etexilate Mesylate23$6,459
Atorvastatin Calcium298$3,038
Losartan Potassium187$2,132
Digoxin76$2,019
Carvedilol156$1,845
Lisinopril146$1,325
ClopidogrelClopidogrel Bisulfate114$1,289
Flecainide Acetate39$1,054
Torsemide28$1,053
Diltiazem 24hr Er (Cd)Diltiazem Hcl52$934

Paid to pharmacies, not to this prescriber.

Companies that both paid and supply prescribed drugs

These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.

CompanyPaid to this providerPart D cost of their drugs
PfizerEliquis$61$377,154437 claims
Johnson & JohnsonXarelto$15$150,603125 claims
NovartisEntresto$306$72,95450 claims

Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 75th percentile of 49 cardiovascular disease providers in Montana.

Other cardiovascular disease in Great Falls

See the full list for Montana

Where these figures come from

Is this you, or does something look wrong? →